Clin Exp Rheumatol: Surfactive protein D associated with 3-month mortality from anti-MDA5 antibody-interstitial lung disease
-
Last Update: 2020-05-29
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
The study was designed to explore the association between serum levels in matrix metalloproteinase 7 (MMP7), surfactoprotein D (SPD), leukone 18 (IL-18) and prosiding factor ligand 18 (CCL18) associated with dermatitis and multiple myositis interstitial pulmonary disease (DM/PM-ILD) and to assess its prognostic value in the diseasewere included in 78 patients diagnosed with DM/PM-ILD by multidisciplinary teams and classified as anti-melanoma differentiation-related protein 5 antibodies (MDA5), anti-synthetic antibodies (ARS)-ILD and other antibodies-ILD based on autoantibodiesCollect clinical data and analyze serum levels of 4 biomarkersThe main endpoint is a three-month mortality rateThe threshold of biomarker-to-mortality was obtained by the analysis of subject's working characteristics (ROC)Cox regression is performed to evaluate the forecastSerum MMP7 (p.0.036), SPD (p.001), IL-18 (p.001) and CCL18 (p.0001) were significantly higher than healthy controls in Patients with DM/PM-ILD, and MMP7 (p.0.029) and (p.029) patients were significantly lower than SSDThe three-month mortality rate for MDA5-ILD was 54.5% (12/22)Multi-factor analysis showed that age (p-0.001, HR 1.151, 95% CI 1.063-1.247) and elevated SPD levels (?75.90 ng/ml, p-0.005, HR 16.411, 95% CI 2.369-113.711) were important predictable indicators of Mortality for Patients with MAD5-ILelevated serum biomarkers are associated with DM/PM-ILD, and there are differences between MDA5-ILD and ARS-ILDAge and SPD increases can predict short-term mortality in patients with MDA5-ILDThis study provides important clues to understand the classification and prognosis of DM/PM-ILD
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.